Stock Research: Sino Biopharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Sino Biopharmaceutical

HKG:1177 KYG8167W1380
71
  • Value
    52
  • Growth
    63
  • Safety
    Safety
    32
  • Combined
    45
  • Sentiment
    84
  • 360° View
    360° View
    71
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANALYSIS: With an Obermatt 360° View of 71 (better than 71% compared with alternatives), overall professional sentiment and financial characteristics for the stock Sino Biopharmaceutical are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Sino Biopharmaceutical. The consolidated Value Rank has an attractive rank of 52, which means that the share price of Sino Biopharmaceutical is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 52% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 63, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 84. But the company’s financing is risky with a Safety rank of 32. This means 68% of comparable companies have a safer financing structure than Sino Biopharmaceutical. ...read more

more
Index
Hang Seng
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
52 n/a n/a n/a
Growth
63 n/a n/a n/a
Safety
Safety
32 n/a n/a n/a
Sentiment
84 n/a n/a n/a
360° View
360° View
71 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 n/a n/a n/a
Opinions Change
30 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
88 n/a n/a n/a
Sentiment
84 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
52 n/a n/a n/a
Growth
63 n/a n/a n/a
Safety Safety
32 n/a n/a n/a
Combined
45 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
44 n/a n/a n/a
Price vs. Earnings (P/E)
40 n/a n/a n/a
Price vs. Book (P/B)
29 n/a n/a n/a
Dividend Yield
85 n/a n/a n/a
Value
52 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
66 n/a n/a n/a
Profit Growth
81 n/a n/a n/a
Capital Growth
6 n/a n/a n/a
Stock Returns
87 n/a n/a n/a
Growth
63 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
50 n/a n/a n/a
Refinancing
6 n/a n/a n/a
Liquidity
76 n/a n/a n/a
Safety Safety
32 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Sino Biopharmaceutical and broaden your portfolio horizons.

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Perusahaan Perkebunan London Sumatra Indonesia

JKT:LSIP
Country: Hong Kong
Industry: Agricultural Products
Size: Medium
Full Stock Analysis

CK Asset Holdings

HKG:1113
Country: Hong Kong
Industry: Real Estate Development
Size: X-Large
Full Stock Analysis

Astra Otoparts

JKT:AUTO
Country: Hong Kong
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: